{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:15:55Z","timestamp":1749096955852,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02844-1","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:19:13Z","timestamp":1749061153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines"],"prefix":"10.1007","volume":"16","author":[{"given":"Sahar","family":"Khojastehpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azarmidokht","family":"Aminazad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh","family":"Abdolahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Samareh-Salavati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrin","family":"Momeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"9","key":"2844_CR1","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.955684","volume":"3","author":"H-A Michaud","year":"2014","unstructured":"Michaud H-A, Eliaou J-F, Lafont V, Bonnefoy N, Gros LJO. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology. 2014;3(9): e955684.","journal-title":"Oncoimmunology"},{"issue":"9","key":"2844_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2844_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2844_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2844_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397.","journal-title":"EMBO Mol Med"},{"issue":"5562","key":"2844_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100.","journal-title":"Science"},{"issue":"5562","key":"2844_CR7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1126\/science.1070538","volume":"295","author":"K K\u00e4rre","year":"2002","unstructured":"K\u00e4rre K. A perfect mismatch. Science. 2002;295(5562):2029\u201331.","journal-title":"Science"},{"key":"2844_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3389\/fimmu.2020.00812","volume":"11","author":"A Pfefferle","year":"2020","unstructured":"Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg K. Deciphering natural killer cell homeostasis. Front Immunol. 2020;11:812. https:\/\/doi.org\/10.3389\/fimmu.2020.00812. (Epub 2020\/06\/02).","journal-title":"Front Immunol"},{"issue":"1","key":"2844_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, et al. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.","journal-title":"BMC Cancer"},{"issue":"1","key":"2844_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40814-023-01355-6","volume":"9","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Hashemi ZS, Sanati H, Abbasvandi F, Yunesian M, et al. Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19. Pilot Feasibil Stud. 2023;9(1):137.","journal-title":"Pilot Feasibil Stud"},{"issue":"1","key":"2844_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7.","journal-title":"Nat Rev Cancer"},{"key":"2844_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fmed.2015.00093","volume":"2","author":"RS Mehta","year":"2016","unstructured":"Mehta RS, Shpall EJ, Rezvani K. Cord blood as a source of natural killer cells. Front Med. 2016;2:93.","journal-title":"Front Med"},{"key":"2844_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","volume":"8","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:329.","journal-title":"Front Immunol"},{"issue":"7776","key":"2844_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","journal-title":"Nature"},{"key":"2844_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fimmu.2015.00202","volume":"6","author":"A Gras Navarro","year":"2015","unstructured":"Gras Navarro A, Bj\u00f6rklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202.","journal-title":"Front Immunol"},{"issue":"12","key":"2844_CR16","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","volume":"73","author":"S Rusakiewicz","year":"2013","unstructured":"Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Can Res. 2013;73(12):3499\u2013510.","journal-title":"Can Res"},{"issue":"21","key":"2844_CR17","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1158\/0008-5472.CAN-11-0792","volume":"71","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Can Res. 2011;71(21):6621\u201332.","journal-title":"Can Res"},{"issue":"5","key":"2844_CR18","first-page":"383","volume":"13","author":"Z Ghazvinian","year":"2023","unstructured":"Ghazvinian Z, Abdolahi S, Ahmadvand M, Emami AH, Muhammadnejad S, Aghdaei HA, et al. Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model. Bioimpacts. 2023;13(5):383.","journal-title":"Bioimpacts"},{"issue":"6","key":"2844_CR19","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/eji.201344272","volume":"44","author":"M Vitale","year":"2014","unstructured":"Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014;44(6):1582\u201392.","journal-title":"Eur J Immunol"},{"issue":"7","key":"2844_CR20","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, Della Chiesa M, Sivori S, Mingari MC, Pende D, Moretta L. Human NK cells, their receptors and function. Eur J Immunol. 2021;51(7):1566\u201379.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2844_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"8","key":"2844_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Mar\u00e7ais","year":"2014","unstructured":"Mar\u00e7ais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15(8):749\u201357.","journal-title":"Nat Immunol"},{"issue":"1","key":"2844_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol Ther. 2020;28(1):52\u201363.","journal-title":"Mol Ther"},{"key":"2844_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-0716-0338-3_18","volume":"2121","author":"M Lambert","year":"2020","unstructured":"Lambert M, Leijonhufvud C, Segerberg F, Melenhorst JJ, Carlsten M. CRISPR\/Cas9-based gene engineering of human natural killer cells: protocols for knockout and readouts to evaluate their efficacy. Innate Lymphoid Cells Methods Protoc. 2020;2121:213\u201339.","journal-title":"Innate Lymphoid Cells Methods Protoc"},{"issue":"5","key":"2844_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/stemcells.19-5-378","volume":"19","author":"DL Krebs","year":"2001","unstructured":"Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem cells. 2001;19(5):378\u201387.","journal-title":"Stem cells"},{"issue":"3","key":"2844_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cytogfr.2013.03.005","volume":"24","author":"EM Linossi","year":"2013","unstructured":"Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev. 2013;24(3):241\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"2844_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar1741","volume":"7","author":"A Yoshimura","year":"2005","unstructured":"Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005;7(3):1\u201311.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2844_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1471-4892(03)00070-5","volume":"3","author":"K Inagaki-Ohara","year":"2003","unstructured":"Inagaki-Ohara K, Hanada T, Yoshimura A. Negative regulation of cytokine signaling and inflammatory diseases. Curr Opin Pharmacol. 2003;3(4):435\u201342.","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"2844_CR29","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/eji.202149710","volume":"52","author":"D Palacios","year":"2022","unstructured":"Palacios D, Momayyezi P, Huhn O, Ask EH, Dunst J, Malmberg KJ, et al. An optimized platform for efficient siRNA delivery into human NK cells. Eur J Immunol. 2022;52(7):1190.","journal-title":"Eur J Immunol"},{"key":"2844_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/375253","author":"J Cursons","year":"2018","unstructured":"Cursons J, Souza-Fonseca-Guimaraes F, Anderson A, Foroutan M, Hediyeh-Zadeh S, Behren A, et al. A natural killer cell gene signature predicts melanoma patient survival. bioRxiv. 2018. https:\/\/doi.org\/10.1101\/375253.","journal-title":"bioRxiv"},{"issue":"2","key":"2844_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","volume":"40","author":"F Souza-Fonseca-Guimaraes","year":"2019","unstructured":"Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 2019;40(2):142\u201358.","journal-title":"Trends Immunol"},{"key":"2844_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fimmu.2020.00075","volume":"11","author":"RB Delconte","year":"2020","unstructured":"Delconte RB, Guittard G, Goh W, Hediyeh-Zadeh S, Hennessy RJ, Rautela J, et al. NK cell priming from endogenous homeostatic signals is modulated by CIS. Front Immunol. 2020;11:75.","journal-title":"Front Immunol"},{"issue":"5","key":"2844_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694\u2013704.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2844_CR34","first-page":"2515","volume":"131","author":"R Romee","year":"2018","unstructured":"Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood J Am Soc Hematol. 2018;131(23):2515\u201327.","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"2844_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell. 2020;27(2):224-37.e6.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2844_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004244","volume":"10","author":"P-L Bernard","year":"2022","unstructured":"Bernard P-L, Delconte R, Pastor S, Laletin V, Da Silva CC, Goubard A, et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J Immunother Cancer. 2022;10(5): e004244.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2844_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1267892","volume":"6","author":"EM Putz","year":"2017","unstructured":"Putz EM, Guillerey C, Kos K, Stannard K, Miles K, Delconte RB, et al. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology. 2017;6(2): e1267892.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2844_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","volume":"42","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al. CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J Exp Clin Cancer Res. 2023;42(1):205.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2844_CR39","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/cancers12092659","volume":"12","author":"DA Vallera","year":"2020","unstructured":"Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, et al. NK-cell-mediated targeting of various solid tumors using a B7\u2013H3 tri-specific killer engager in vitro and in vivo. Cancers. 2020;12(9):2659.","journal-title":"Cancers"},{"issue":"2","key":"2844_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.canlet.2008.07.016","volume":"272","author":"C-Y Lin","year":"2008","unstructured":"Lin C-Y, Chuang T-F, Liao K-W, Huang Y-J, Pai C-C, Chu R-M. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett. 2008;272(2):285\u201395.","journal-title":"Cancer Lett"},{"issue":"2","key":"2844_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006002","volume":"11","author":"J Bi","year":"2023","unstructured":"Bi J, Huang C, Jin X, Zheng C, Huang Y, Zheng X, et al. TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells. J ImmunoTher Cancer. 2023;11(2): e006002.","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"2844_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 2018;3(3): e96219.","journal-title":"JCI Insight"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02844-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:19:23Z","timestamp":1749061163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02844-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02844-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Tehran University of Medical Sciences ethically approved the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1004"}}